Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010410 | 1.00 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1DPP4FPR2MEN1 | |
| SCHEMBL6010210 | 0.85 | PDCD1LG2 (0.35) | ALDH1A1DPP4CA2CA1MME | |
| SCHEMBL28325810 | 0.85 | DPP4 (0.39) | ALDH1A1DPP4MAPK1 | |
| SCHEMBL28325811 | 0.85 | DPP4 (0.39) | ALDH1A1DPP4MAPK1 | |
| SCHEMBL6010220 | 0.85 | PDCD1LG2 (0.35) | ALDH1A1DPP4CA2CA1MME | |
| Glycerin SCHEMBL1944312 | 0.83 | DPP4 (0.38) | ALDH1A1DPP4MAPK1 | |
| SCHEMBL6373080 | 0.82 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1DPP4FPR2MEN1 | |
| SCHEMBL28775547 | 0.80 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1FPR2MEN1KMT2A | |
| SCHEMBL3154720 | 0.80 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1FPR2MEN1KMT2A | |
| SCHEMBL6010263 | 0.76 | OR51E2 (0.37) | ALDH1A1MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | ALDH1A1 819/4885L3MBTL1 3939/4885DPP4 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.